Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR1E | P28566 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634148 | 0.83 | LMNA (0.44) | CYP2D6SRCLMNAGAAMEN1 | |
| SCHEMBL2763355 | 0.83 | LMNA (0.47) | LMNAMEN1MAPTHTR1EKMT2A | |
| SCHEMBL16347968 | 0.82 | CYP2D6 (0.43) | CYP2D6SRCLMNAMAPK1GAA | |
| SCHEMBL16347967 | 0.82 | CYP2D6 (0.43) | CYP2D6SRCLMNAMAPK1GAA | |
| SCHEMBL942928 | 0.75 | KDM4E (0.40) | CYP2D6SRCLMNAMAPK1GAA | |
| SCHEMBL66920 | 0.75 | LMNA (0.54) | CYP2D6SRCLMNAMAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL11359974 | 0.73 | LMNA (0.53) | CYP2D6SRCLMNAMAPK1GAA | |
| SCHEMBL7799097 | 0.73 | CYP3A4 (0.47) | CYP2D6CYP3A4CYP1A2TSHRSLC6A3 | |
| SCHEMBL7799095 | 0.73 | CYP3A4 (0.47) | CYP2D6CYP3A4CYP1A2TSHRSLC6A3 | |
| SCHEMBL16143791 | 0.72 | CA1 (0.50) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546099-B1 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-12-31 | — | — | EP | disclosed |
| US-7399779-B2 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-07-15 | — | — | US | disclosed |
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1546099-A4 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-02 | — | — | EP | disclosed |
| EP-1546099-A2 | 3,6-DISUBSTITUTED AZABICYCLO 3.1.0 HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004004629-A2 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004791-A1 | 3,6-disubstituted azabicyclo {3.1.0} hexane derivatives useful as muscarnic receptor antagonists | CHRM3, CHRM5, CHRM2 | CYP2D6 211/4885SRC 3517/4885LMNA 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.